Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

NCT03891485 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT03891485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
Lead sponsor
National Cancer Institute, Naples
Phase
Observational
Overall status
Completed
Start date
December 31, 2016
Completion date
August 30, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, rcc